Maxim Group Upgrades Galmed Pharmaceuticals to Buy, Announces $4 Price Target
Maxim Group Upgrades Galmed Pharmaceuticals to Buy, Announces $4 Price Target
Maxim Group 將Galmed Pharmicals升級爲收購,宣佈目標股價爲4美元
Maxim Group analyst Jason McCarthy upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Hold to Buy and announces $4 price target.
Maxim集團分析師傑森·麥卡錫將Galmed Pharmicals(納斯達克股票代碼:GLMD)從持有上調至買入,並宣佈目標股價爲4美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。